Golden
Cala Health

Cala Health

A medical technology company developing neuroperipheral therapy, a new class of electrical medicine aimed at treating chronic disease with wearable electronics.

Neuroperipheral therapy stimulates peripheral nerves with body-worn electronics and has the potential to treat chronic diseases non-invasively. Cala Health is working on a treatment for Essential Tremor (ET), a movement disorder that makes it difficult to perform daily activities like eating and writing. Cala Health supports the International Essential Tremor Foundation (IETF). 



In December 2018, Cala Health launched a clinical trail for its wrist-worn neurostimulator in treatment of ET. Their Cala One device achieved FDA clearance in April 2018 for transient relief in adults of ET. The clinical trial has 500 patients in a single-arm Prospect trial which will evaluate the Cala Two device at relieving symptoms for three months, with treatments twice per day at 40 minutes each. 



Timeline

People

Name
Role
Related Golden topics

Chris Daniel

VP, Commercial Operations



John Colombo

VP of Product Development and Operations



Kate Rosenbluth, PhD

CEO



Kristie Burns

Chief Marketing Officer



Manish Gupta

VP of Clinical Affairs



Scott Wilson, PhD

VP of Quality Assurance and Regulatory Affairs



Further reading

Title
Author
Link
Type
Date









Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References